Athanase Innovation AB (ATIN) fair value: what the stock is really worth
As of Sep 21, 2026: fair value of Athanase Innovation AB SEK 9.08, price SEK 20.20, upside -55.1%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Athanase Innovation AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 10.80 – kr 167.67 · fair‑value band kr 5.99 – kr 11.35 · the kr 20.20 price screens above the kr 9.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Athanase Innovation in your weekly email
Every Wednesday you see whether Athanase Innovation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Athanase Innovation AB is public investment firm. The company invests in private and public technology and innovation companies. It also develops and sells machine inspection unit, used for automatic quality control, inspection and measurement of pallets. Athanase Innovation AB was founded in 2016 and is based in Stockholm, Sweden.
Stock analysis
Athanase Innovation AB (ATIN) currently trades at kr 20.20, while our model-based Fair Value estimate is kr 9.08, implying the stock looks roughly 122.5% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: kr 5.99 (bear) to kr 11.35 (bull), the price of kr 20.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Financial Services sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Athanase Innovation AB reported revenue of 36.9M SEK in FY2026 versus 7.1M SEK in FY2022, a compound +51.2%/yr. Reported net income was −57.6M SEK in FY2026.
Key figures
Market cap 485M SEK (≈ $48.9M) · P/E ratio 0.0 · P/S ratio 10.3 · EPS (TTM) kr 891.67 · Net margin −124% · Return on equity −13.3% · Return on assets (EBIT) −9.3% · Operating margin −65.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 6% below its 52-week high and 68% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −4% fair-value upside, at −55%, ATIN screens richer than that median.
Fair Value models
Bear kr 5.99Fair Value kr 9.08Bull kr 11.35
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 3 months old). Earnings retained since then (kr 210.09 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−79.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+79.4%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
’18
’19
’20
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
51.8% (2020) → −220.9% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Asset Management · 658 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score42 · Bottom 25%
Fair Value upside−55% · Bottom 25%
Profitability
Return on assets−8% · Bottom 25%
Net margin (TTM)−124% · Bottom 25%
Operating margin (TTM)−66% · Bottom 25%
Growth and dividend
Revenue growth−4% · Below median
Balance sheet
Debt / equity0.92× · Highest 25%
Valuation Multiplesvs Asset Management median · lower = cheaper
P/E (TTM)0.0× · Cheapest 25%
P/B0.11× · Cheapest 25%
P/S (TTM)1.04× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 54
FUTURE (revenue growth)0· sector 21
PAST (return on equity)0· sector 22
HEALTH (low debt)54· sector 95
DIVIDEND (yield)0· sector 81
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Athanase Innovation AB Fair Value". https://www.fairvalue-calculator.com/stock/ATIN
Frequently asked questions
Is Athanase Innovation AB (ATIN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 9.08 versus a price of kr 20.20, about −55% upside (overvalued).
What is the fair value of ATIN?
Our model-based fair value for Athanase Innovation AB is kr 9.08 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 20.20.
What is the quality score of ATIN?
Athanase Innovation AB has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Athanase Innovation AB (ATIN)?
Our model-based price target is the fair value of kr 9.08 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 5.99, optimistic scenario kr 11.35. It is a calculation from audited fundamentals, not an analyst target.
What is the Athanase Innovation AB stock forecast for 2026?
Our models put fair value at kr 9.08, about −55% upside versus a price of kr 20.20 (overvalued). Cautious scenario kr 5.99, optimistic scenario kr 11.35. The calculation is refreshed regularly with new filings.
What is the revenue of Athanase Innovation AB (ATIN)?
Athanase Innovation AB reported trailing-twelve-month revenue of about 46.9M SEK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Athanase Innovation AB (ATIN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Athanase Innovation AB it is kr 9.08 per share (as of Sep 24, 2026), against a price of kr 20.20. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Athanase Innovation AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ATIN trades above its calculated fair value: price kr 20.20, fair value kr 9.08, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATIN?
No. The price is what the market pays today (kr 20.20); the fair value is what the company's own numbers justify (kr 9.08). For Athanase Innovation AB the two are kr 11.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Athanase Innovation AB worth?
The market values Athanase Innovation AB at about 485M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 20.20; our models calculate a fair value of kr 9.08 per share.
What do the bullish and bearish scenarios say about ATIN?
Our models span a range for Athanase Innovation AB: cautious scenario kr 5.99, base kr 9.08, optimistic kr 11.35 per share (as of Sep 24, 2026, price kr 20.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ATIN?
Athanase Innovation AB trades at a price-to-earnings ratio of 0.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 9.08 is built from several models across several years. Other multiples: P/B 0.1, P/S 1.0.
How solid is the balance sheet of Athanase Innovation AB (ATIN)?
Balance-sheet figures for Athanase Innovation AB (as of Sep 24, 2026): return on equity −13.3%, debt of 0.92 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is ATIN from its 52-week high?
Athanase Innovation AB trades at kr 20.20, about 6% below its 52-week high of kr 21.60 and 68% above the low of kr 12.00 (as of Sep 21, 2026). Distance from the high says nothing about value: that is what the fair value of kr 9.08 is for.
Which stocks are comparable to Athanase Innovation AB?
From the same area (Financial Services) we also value Blackstone Inc, Brookfield Corporation, KKR & Co, Apollo Global Management, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Athanase Innovation AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 20.20, calculated fair value kr 9.08 (−55%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ATIN calculated?
We run Athanase Innovation AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 9.08, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Athanase Innovation AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Athanase Innovation AB (ATIN)?
The closing price on Sep 21, 2026 was kr 20.20. Our model-based fair value is kr 9.08, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Athanase Innovation AB right now?
The price sits above even our optimistic bull case (kr 11.35). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 5.99 to kr 11.35) leaves room in how you read the outcome.
Key figures of Athanase Innovation AB
How large is the market capitalisation of Athanase Innovation AB (ATIN)?
The market capitalisation of Athanase Innovation AB is 485M SEK (≈ $48.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Athanase Innovation AB (ATIN)?
The price-to-sales ratio of Athanase Innovation AB is 10.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Athanase Innovation AB (ATIN)?
Earnings per share at Athanase Innovation AB are kr 891.67 (price ÷ EPS = P/E 0.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Athanase Innovation AB (ATIN)?
The net margin of Athanase Innovation AB is −124% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Athanase Innovation AB (ATIN)?
The return on equity (ROE) of Athanase Innovation AB is −13.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Athanase Innovation AB (ATIN)?
On an EBIT basis the return on assets of Athanase Innovation AB is −9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Athanase Innovation AB (ATIN)?
The operating margin of Athanase Innovation AB is −65.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Athanase Innovation AB (ATIN)?
Revenue at Athanase Innovation AB is growing −4.3% versus a year earlier (3y avg +79.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Athanase Innovation AB (ATIN)?
Earnings per share at Athanase Innovation AB are growing −9.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Athanase Innovation AB (ATIN) generate?
The free cash flow of Athanase Innovation AB is −67.5M SEK (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Athanase Innovation AB (ATIN) hold?
Athanase Innovation AB holds more cash than debt, 245M SEK net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Athanase Innovation AB in the live analysis
One click puts Athanase Innovation AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
